Cigna modified MM 0028 covering BNP and NT-proBNP testing in the outpatient setting, effective October 16, 2025. Here's what billing teams need to know before that date.
Cigna Healthcare updated coverage policy MM 0028, which governs plasma brain natriuretic peptide (BNP) and NT-proBNP measurement in outpatient settings. The change affects three CPT codes — 83880, 0309U, and 0310U — and spans 139 ICD-10-CM diagnosis codes covering cardiovascular disease, diabetes, hypertension, valve disorders, and more. If your practice bills these markers for heart failure evaluation, Kawasaki disease workup, or cardiovascular risk assessment, this policy change is your roadmap for what Cigna will and won't pay.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Plasma Brain Natriuretic Peptide in the Outpatient Setting |
| Policy Code | MM 0028 |
| Change Type | Modified |
| Effective Date | October 16, 2025 |
| Impact Level | High |
| Specialties Affected | Cardiology, Internal Medicine, Pediatrics, Nephrology, Endocrinology, Pulmonology |
| Key Action | Audit charge capture for CPT 83880, 0309U, and 0310U and confirm diagnosis pairing against the updated ICD-10-CM list before October 16, 2025 |
Cigna BNP and NT-proBNP Coverage Criteria and Medical Necessity Requirements 2025
The Cigna BNP coverage policy under MM 0028 covers CPT 83880 (natriuretic peptide), CPT 0309U, and CPT 0310U when medical necessity criteria are met. All three codes are designated "Considered Medically Necessary when criteria in the applicable coverage position are met." That's standard Cigna language — but the real work is in the diagnosis pairing.
Cigna requires a supported ICD-10-CM diagnosis to establish medical necessity for BNP and NT-proBNP billing. With 139 covered diagnosis codes, the list is broad — but that breadth cuts both ways. It means there's no excuse for missing a valid indication, and there's no room for sloppy code selection when the patient's chart supports a more specific code.
The three CPT codes serve different clinical purposes, and Cigna treats them differently in practice. CPT 83880 is the standard natriuretic peptide assay — the workhorse of outpatient heart failure diagnosis and monitoring. CPT 0309U is a proprietary multianalyte assay for cardiovascular disease risk, analyzing four proteins; the source description identifies NT-proBNP and osteopontin among them. Consult the full MM 0028 policy for the complete panel composition before billing. CPT 0310U is a pediatric-specific panel for Kawasaki disease evaluation. The source description identifies NT-proBNP and C-reactive protein among the biomarkers analyzed; consult the full policy for the complete biomarker list.
Misrouting a pediatric KD workup through CPT 83880 instead of CPT 0310U — or billing the multianalyte panel 0309U when only a standalone BNP was ordered — is a direct path to claim denial. Get the CPT-to-clinical-indication match right before submission.
Regarding prior authorization: MM 0028 does not explicitly call out a prior authorization requirement for BNP testing in the outpatient setting under this policy. However, prior auth requirements can live at the plan level, not just the coverage policy level. If your patients are on managed care or ACA exchange plans administered by Cigna, verify auth requirements through eligibility checks before the first bill goes out.
Cigna BNP Testing Exclusions and Non-Covered Indications
MM 0028 does not list a separate "not covered" or "experimental/investigational" designation for BNP or NT-proBNP testing under the three affected codes. All three codes carry a single coverage position: medically necessary when criteria are met. There is no bifurcation into covered vs. experimental tiers within this policy.
The real risk here isn't an explicit exclusion — it's a diagnosis mismatch. If you bill CPT 83880 with a diagnosis code that isn't on Cigna's supported ICD-10-CM list for this policy, you're looking at a medical necessity denial, not a coverage exclusion. That's an important distinction. A coverage exclusion is harder to overturn. A medical necessity denial has an appeal path — but it's also avoidable if your coding team validates the diagnosis pairing at charge capture.
Coverage Indications at a Glance
| Indication | Status | Relevant CPT Codes | Notes |
|---|---|---|---|
| Cardiovascular disease / NT-proBNP multianalyte risk panel | Covered when criteria met | 0309U | 4-protein panel; consult the full MM 0028 policy for complete panel composition before billing 0309U |
| Kawasaki disease evaluation (pediatric) | Covered when criteria met | 0310U | Pediatric-specific; consult the full MM 0028 policy for the complete biomarker list |
| Natriuretic peptide measurement (standalone BNP/NT-proBNP) | Covered when criteria met | 83880 | Applies across the broad ICD-10 diagnosis range below |
| Heart failure and additional cardiac diagnoses | See note | 83880 | See the full 139-code ICD-10-CM list at the Cigna MM 0028 policy page to confirm specific I50.x code coverage |
| Hypertension and hypertensive heart disease (I10, I11.x, I13.x, I15.x, I16.x, I1A.0) | Covered when criteria met | 83880 | Includes resistant hypertension (I1A.0) |
| Acute MI and coronary artery disease (I21.x, I22.x, I25.x) | Covered when criteria met | 83880 | Broad code range; use most specific MI type code available |
| Pulmonary hypertension (I27.x) | Covered when criteria met | 83880 | Secondary pulmonary hypertension included (I27.20–I27.29) |
| Valvular heart disease (I05.x–I09.x) | Covered when criteria met | 83880 | Rheumatic and non-rheumatic valve disorders |
| Diabetes mellitus with cardiac risk (E10.x, E11.x, E13.x) | Covered when criteria met | 83880 | Supports BNP use in diabetic cardiac monitoring |
| Obesity and metabolic syndrome (E66.x, E88.810–E88.819) | Covered when criteria met | 83880 | Metabolic syndrome codes now explicit in the list |
| Amyloidosis (E85.0–E85.9) | Covered when criteria met | 83880 | Relevant for cardiac amyloid workup |
| Multiple myeloma (C90.0x) | Covered when criteria met | 83880 | Ties to cardiac monitoring in hematologic malignancy |
| Cytokine release syndrome, grade 2 (D89.832) | Covered when criteria met | 83880 | CRS-related cardiac monitoring; newer addition to the indication list |
Cigna BNP Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for CPT 83880, 0309U, and 0310U before October 16, 2025. Pull claims from the past 90 days and check that every claim has a paired ICD-10-CM code that appears on the MM 0028 diagnosis list. Any mismatches are denials waiting to happen under the new criteria. |
| 2 | Separate your 0309U and 0310U billing from 83880 — they are not interchangeable. CPT 0309U is a proprietary multianalyte assay for adult cardiovascular disease risk. CPT 0310U is a pediatric Kawasaki disease panel. If your cardiology group orders a cardiovascular disease risk panel and your pediatric team orders a KD workup, each needs its own correct CPT. Billing 83880 as a substitute for either proprietary code misrepresents the service and will fail on audit. |
| 3 | Update your superbill or order set to include the newer ICD-10 codes now in the MM 0028 list. Codes like I1A.0 (resistant hypertension), I25.85 (chronic coronary microvascular dysfunction), and D89.832 (cytokine release syndrome, grade 2) are clinically relevant and now explicitly supported. If your charge capture templates don't include these, your coders will default to less specific codes and leave valid claims at risk. |
| 4 | Document the outpatient setting explicitly in the medical record. MM 0028 applies to outpatient BNP measurement specifically. If a patient transitions from observation to inpatient status, the coverage rules shift. Make sure your documentation distinguishes the care setting at the time of the order. |
| 5 | Verify prior auth requirements at the plan level. MM 0028 doesn't mandate prior authorization for BNP testing at the policy level, but individual Cigna plan designs vary. Run eligibility and benefits checks for any Cigna managed care or exchange plan patient before the effective date of October 16, 2025. A coverage policy that allows a service doesn't override a plan-level prior auth requirement. |
| 6 | Train your coders on the breadth of this diagnosis list. With 139 ICD-10-CM codes, there are valid BNP indications in cardiology, endocrinology, nephrology, oncology, and pediatrics. Many billing teams treat BNP as purely a heart failure code. It isn't — and missing a valid diagnosis pairing means leaving covered claims unbilled. |
If your practice has high volume on any of these codes and you're uncertain how the updated criteria map to your patient mix, loop in your compliance officer before October 16.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for BNP and NT-proBNP Testing Under MM 0028
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 83880 | CPT | Natriuretic peptide |
| 0309U | CPT | Cardiology (cardiovascular disease), analysis of 4 proteins including NT-proBNP and osteopontin; consult the full MM 0028 policy for complete panel composition |
| 0310U | CPT | Pediatrics (vasculitis, Kawasaki disease [KD]), multianalyte panel including NT-proBNP and C-reactive protein; consult the full MM 0028 policy for complete biomarker list |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C90.0x | Multiple myeloma |
| D89.832 | Cytokine release syndrome, grade 2 |
| E10.10–E10.9 | Type 1 diabetes mellitus |
| E11.00–E11.A | Type 2 diabetes mellitus |
| E13.00–E13.9 | Other specified diabetes mellitus |
| E66.0–E66.9 | Overweight and obesity |
| E85.0–E85.9 | Amyloidosis |
| E88.810–E88.819 | Metabolic syndrome and other insulin resistance |
| I05.0–I05.9 | Rheumatic mitral valve diseases |
| I06.0–I06.9 | Rheumatic aortic valve diseases |
| I07.0–I07.9 | Rheumatic tricuspid valve diseases |
| I08.0–I08.9 | Multiple valve diseases |
| I09.0–I09.9 | Other rheumatic heart diseases |
| I10 | Essential (primary) hypertension |
| I11.0–I11.9 | Hypertensive heart disease |
| I13.0–I13.2 | Hypertensive heart and chronic kidney disease |
| I15.0–I15.9 | Secondary hypertension |
| I16.0–I16.9 | Hypertensive crisis |
| I1A.0 | Resistant hypertension |
| I20.0–I20.9 | Angina pectoris |
| I21.01–I21.09 | ST elevation (STEMI) myocardial infarction of anterior wall |
| I21.11–I21.19 | ST elevation (STEMI) myocardial infarction of inferior wall |
| I21.21–I21.29 | ST elevation (STEMI) myocardial infarction of other sites |
| I21.3 | ST elevation (STEMI) myocardial infarction of unspecified site |
| I21.4 | Non-ST elevation (NSTEMI) myocardial infarction |
| I21.9 | Acute myocardial infarction, unspecified |
| I21.A1–I21.A9 | Other type of myocardial infarction |
| I21.B | Myocardial infarction with coronary microvascular dysfunction |
| I22.0–I22.9 | Subsequent STEMI and NSTEMI myocardial infarction |
| I24.0 | Acute coronary thrombosis not resulting in myocardial infarction |
| I24.81–I24.89 | Other forms of acute ischemic heart disease |
| I24.9 | Acute ischemic heart disease, unspecified |
| I25.10 | Atherosclerotic heart disease of native coronary artery without angina pectoris |
| I25.110–I25.119 | Atherosclerotic heart disease of native coronary artery with angina pectoris |
| I25.2 | Old myocardial infarction |
| I25.3 | Aneurysm of heart |
| I25.41–I25.42 | Coronary artery aneurysm and dissection |
| I25.5 | Ischemic cardiomyopathy |
| I25.6 | Silent myocardial ischemia |
| I25.700–I25.709 | Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris |
| I25.710–I25.719 | Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris |
| I25.720–I25.729 | Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris |
| I25.730–I25.739 | Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris |
| I25.750–I25.759 | Atherosclerosis of native coronary artery of transplanted heart with angina pectoris |
| I25.760–I25.769 | Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris |
| I25.790–I25.799 | Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris |
| I25.810–I25.812 | Atherosclerosis of other coronary vessels without angina pectoris |
| I25.82 | Chronic total occlusion of coronary artery |
| I25.83 | Coronary atherosclerosis due to lipid rich plaque |
| I25.84 | Coronary atherosclerosis due to calcified coronary lesion |
| I25.85 | Chronic coronary microvascular dysfunction |
| I25.89 | Other forms of chronic ischemic heart disease |
| I25.9 | Chronic ischemic heart disease, unspecified |
| I27.0–I27.1 | Other pulmonary heart diseases |
| I27.20–I27.29 | Other secondary pulmonary hypertension |
The full ICD-10-CM list under MM 0028 includes 139 codes. The 59 additional codes cover further cardiac, renal, and systemic diagnoses. Access the complete list at the Cigna MM 0028 policy page.
Get the Full Picture for CPT 83880
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.